Accustem Sciences (ACUT) Other Non-Current Assets (2025 - 2026)
Accustem Sciences (ACUT) posted quarterly Other Non-Current Assets of $1.5 million for Q1 2026, little changed quarter-over-quarter from $1.5 million in Q4 2025.
Accustem Sciences (ACUT) Other Non-Current Assets (2025 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Other Non-Current Assets for 2 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.5 million, changed N/A from the prior year.
- Other Non-Current Assets steadied at $1.5 million in Q1 2026 per ACUT's latest filing, from $1.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.5 million in Q4 2025 and bottomed at $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Accustem Sciences | 3.54 Mn | 3.52 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |